AbbVie
ABBV
$185.55
Share price
0.97%
Change (1 day)
7.42%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) Fails to deliver data
Key failure to deliver metrics for AbbVie:
- Last SEC data release: 2025-05-30
- Last 15 days FTD volume: $0.36 M
- Last 3 months FTD volume: $33.49 M
- Last year FTD volume: $33.49 M
A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.
Failures to deliver for AbbVie (ABBV) - 3 months history
Number of shares, 3 months chart
Biweekly Failures to deliver volume for AbbVie (ABBV) - since 2013
Volume in USD (price x number of shares), data since 2013AbbVie (ABBV) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2025 | $47.79 M | -75.77% |
| 2024 | $0.19 B | -13.93% |
| 2023 | $0.22 B | -63.52% |
| 2022 | $0.62 B | 629.28% |
| 2021 | $86.13 M | -77.97% |
| 2020 | $0.39 B | 85.64% |
| 2019 | $0.21 B | -52.97% |
| 2018 | $0.44 B | 269.88% |
| 2017 | $0.12 B | -48.45% |
| 2016 | $0.23 B | -37.53% |
| 2015 | $0.37 B | -44.13% |
| 2014 | $0.67 B | 2387.79% |
| 2013 | $27.05 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3 months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Pfizer PFE | $28.79 M | $0.35 B | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $14.98 M | $0.27 B | 🇺🇸 USA |
 Eli Lilly LLY | $26.07 M | $0.20 B | 🇺🇸 USA |
 Amgen AMGN | $82.72 M | $0.33 B | 🇺🇸 USA |
 Gilead Sciences GILD | $0.16 B | $0.25 B | 🇺🇸 USA |
 Biogen BIIB | $7.8 M | $63.66 M | 🇺🇸 USA |
 GlaxoSmithKline GSK | $97.99 M | $0.32 B | 🇬🇧 UK |
 AstraZeneca AZN | $37.71 M | $0.14 B | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $15.34 M | $31.8 M | 🇺🇸 USA |